Although the current evidence does not link BTK with NLRP3 in the pathophysiology of MS/AD, it is easy to infer the same, given the link between NLRP3 and these diseases [62,63] and taking into account the efficacy of BTKi in these diseases. Here, NLRP3 is linked to myeloid sarcoma.